Skip to content
Homepage
Author:
Aquestive Therapeutics, Inc.
Posted Date:
July 7, 2026
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
Aquestive Therapeutics, Inc.
July 7, 2026
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc.
May 14, 2026
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Aquestive Therapeutics, Inc.
May 12, 2026
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
Aquestive Therapeutics, Inc.
May 6, 2026
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Aquestive Therapeutics, Inc.
March 30, 2026
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
Aquestive Therapeutics, Inc.
March 20, 2026
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
Aquestive Therapeutics, Inc.
March 9, 2026
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Aquestive Therapeutics, Inc.
March 5, 2026
Aquestive Therapeutics to Participate in Upcoming March Investor Conferences
Aquestive Therapeutics, Inc.
February 25, 2026
Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8:00 a.m. ET
Aquestive Therapeutics, Inc.
February 24, 2026
1
2
Next
